The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro.

PubWeight™: 0.92‹?›

🔗 View Article (PMC 1475859)

Published in Radiat Oncol on March 29, 2006

Authors

Amelie Rübel1, René Handrick, Lars H Lindner, Matthias Steiger, Hansjörg Eibl, Wilfried Budach, Claus Belka, Verena Jendrossek

Author Affiliations

1: Department of Radiation Oncology, University of Tuebingen, Germany. amelie.ruebel@med.uni-tuebingen.de

Articles cited by this

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34

Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06

The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 14.94

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90

p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46

PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04

A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (2000) 8.74

Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 6.94

Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol (1998) 3.51

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst (1999) 3.25

Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res (1999) 3.05

Radiation and ceramide-induced apoptosis. Oncogene (2003) 2.68

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer (2002) 1.30

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res (2004) 1.28

Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene (2002) 1.28

Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys (2004) 1.27

Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol (2001) 1.24

Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res (1999) 1.18

Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol (2002) 1.14

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg (1999) 1.13

Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs (2005) 1.13

Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08

Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents (2003) 1.07

D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer (1997) 1.06

A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04

Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother Pharmacol (1999) 0.98

Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene (2001) 0.97

Phospholipid antitumor agents. Med Res Rev (1995) 0.93

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res (1992) 0.93

Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene (2003) 0.93

Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys (2001) 0.93

The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res (2001) 0.90

Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Lett (1999) 0.89

Stress-induced apoptosis: toward a symmetry with receptor-mediated cell death. Apoptosis (2004) 0.88

Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother Pharmacol (2002) 0.86

Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol (1999) 0.86

Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer (1995) 0.83

Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int J Oncol (1999) 0.82

Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother Pharmacol (2002) 0.82

Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Acad Dermatol (1993) 0.82

Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett (2002) 0.81

Anti-epidermal growth factor receptor strategies to enhance radiation action. Curr Med Chem Anticancer Agents (2003) 0.80

Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res (2002) 0.80

Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol (1997) 0.80

Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. Curr Med Chem Anticancer Agents (2003) 0.78

Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur J Cancer (1993) 0.78

Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs (2000) 0.78

Thermoradiotherapy for brain tumors. Three cases of recurrent malignant astrocytoma and review of clinical experience. Am J Clin Oncol (1995) 0.77

Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver. Drug Metab Dispos (1995) 0.77

Articles by these authors

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol (2009) 4.38

Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 3.68

Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol (2009) 3.19

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66

Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med (2007) 2.19

Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol (2007) 2.10

Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol (2013) 1.99

Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol (2010) 1.90

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol (2005) 1.69

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol (2008) 1.65

Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol (2013) 1.59

Evidence-based radiation oncology: oesophagus. Radiother Oncol (2009) 1.55

[Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol (2011) 1.51

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood (2004) 1.44

Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38

Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother (2002) 1.28

Guardians of cell death: the Bcl-2 family proteins. Essays Biochem (2003) 1.28

Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys (2004) 1.27

Therapeutic options for recurrent malignant glioma. Radiother Oncol (2010) 1.26

Ceramide-rich membrane rafts mediate CD40 clustering. J Immunol (2002) 1.24

Unraveling the function of the Rhodospirillum rubrum activator of polyhydroxybutyrate (PHB) degradation: the activator is a PHB-granule-bound protein (phasin). J Bacteriol (2004) 1.24

DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol (2010) 1.21

Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol (2007) 1.21

Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene (2004) 1.20

Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol (2011) 1.20

Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiol (2013) 1.19

Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release (2010) 1.19

[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol (2009) 1.16

MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol (2011) 1.15

Neurofibromatosis. Eur J Med Res (2009) 1.15

Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol (2009) 1.13

Chest wall and intrathoracic desmoid tumors: surgical experience and review of the literature. Eur J Med Res (2009) 1.13

FET-PET for malignant glioma treatment planning. Radiother Oncol (2011) 1.13

Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol (2002) 1.12

DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol (2014) 1.12

Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys (2010) 1.12

Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol (2010) 1.11

Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J (2003) 1.11

18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 1.11

DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol (2009) 1.10

Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol (2008) 1.09

Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol (2012) 1.08

Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08

Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res (2010) 1.08

Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys (2010) 1.07

Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer : beware of one-stop shops? Strahlenther Onkol (2010) 1.06

DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy. Strahlenther Onkol (2007) 1.05

The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol (2010) 1.04

TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene (2005) 1.04

The presumptive magnetosome protein Mms16 is a poly(3-hydroxybutyrate) granule-bound protein (phasin) in Magnetospirillum gryphiswaldense. J Bacteriol (2005) 1.04

Surgery vs. radiotherapy in localized prostate cancer. Which is best? Radiat Oncol (2008) 1.03

Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res (2005) 1.03

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol (2009) 1.03

Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther (2010) 1.03

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies. Oncogene (2005) 1.01

MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol (2011) 1.01

In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta (2007) 1.01

Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J (2004) 1.00

DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol (2008) 0.99

Radiotherapy and "new" drugs-new side effects? Radiat Oncol (2011) 0.98

The role of PDGF in radiation oncology. Radiat Oncol (2007) 0.97

Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97

Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer (2005) 0.96

Apoptotic response of Chang cells to infection with Pseudomonas aeruginosa strains PAK and PAO-I: molecular ordering of the apoptosis signaling cascade and role of type IV pili. Infect Immun (2003) 0.96

Iodine-125 brachytherapy for brain tumours--a review. Radiat Oncol (2012) 0.96

Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharmacol (2009) 0.95

Risk of second malignancies after prostate irradiation? Strahlenther Onkol (2007) 0.94

Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol (2011) 0.94

Choline PET based dose-painting in prostate cancer--modelling of dose effects. Radiat Oncol (2010) 0.94

Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol (2008) 0.94

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis (2007) 0.93

Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene (2003) 0.93

Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers. Biol Blood Marrow Transplant (2005) 0.93

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry (2010) 0.92

Irradiation-induced pneumonitis mediated by the CD95/CD95-ligand system. J Natl Cancer Inst (2006) 0.92

Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. Cancer (2007) 0.92

Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys (2007) 0.92

Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol (2003) 0.92

Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One (2007) 0.92

Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys (2005) 0.92